BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
156.2 EUR
-0.85 (-0.54%)
Taking everything into account, IDP scores 5 out of 10 in our fundamental rating. IDP was compared to 83 industry peers in the Biotechnology industry. IDP is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IDP is cheap, but on the other hand it scores bad on growth. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
IDP had a positive operating cash flow in the past year.
IDP had positive earnings in each of the past 5 years.
IDP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IDP has a Return On Assets of 5.51%. This is in the better half of the industry: IDP outperforms 79.52% of its industry peers.
With a decent Return On Equity value of 8.84%, IDP is doing good in the industry, outperforming 79.52% of the companies in the same industry.
With an excellent Return On Invested Capital value of 9.70%, IDP belongs to the best of the industry, outperforming 84.34% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IDP is in line with the industry average of 12.51%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
With an excellent Profit Margin value of 15.98%, IDP belongs to the best of the industry, outperforming 81.93% of the companies in the same industry.
In the last couple of years the Profit Margin of IDP has declined.
IDP has a Operating Margin of 28.50%. This is amongst the best in the industry. IDP outperforms 84.34% of its industry peers.
In the last couple of years the Operating Margin of IDP has declined.
IDP has a better Gross Margin (75.24%) than 65.06% of its industry peers.
In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
The number of shares outstanding for IDP has been increased compared to 1 year ago.
IDP has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, IDP has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.34 indicates that IDP is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.34, IDP is doing good in the industry, outperforming 74.70% of the companies in the same industry.
IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
The Debt to FCF ratio of IDP (2.78) is better than 81.93% of its industry peers.
IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of IDP (0.35) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.34 |
ROIC/WACC1.18
WACC8.22%
2.3 Liquidity
A Current Ratio of 2.72 indicates that IDP has no problem at all paying its short term obligations.
IDP has a Current ratio of 2.72. This is comparable to the rest of the industry: IDP outperforms 59.04% of its industry peers.
IDP has a Quick Ratio of 2.04. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IDP (2.04) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
IDP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
IDP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 0.56% on average per year.
The Revenue is expected to decrease by -0.63% on average over the next years.
EPS Next Y-7.79%
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
EPS Next 5Y0.56%
Revenue Next Year1.98%
Revenue Next 2Y-1.74%
Revenue Next 3Y-1.31%
Revenue Next 5Y-0.63%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.88, the valuation of IDP can be described as reasonable.
Based on the Price/Earnings ratio, IDP is valued cheaper than 92.77% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.34, IDP is valued rather cheaply.
With a Price/Forward Earnings ratio of 11.85, the valuation of IDP can be described as very reasonable.
IDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 95.18% of the companies in the same industry.
IDP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.88 | ||
| Fwd PE | 11.85 |
4.2 Price Multiples
87.95% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 91.57% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.8 | ||
| EV/EBITDA | 7.97 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (12/8/2025, 7:00:00 PM)
156.2
-0.85 (-0.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.4%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap22.91B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target155.46 (-0.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)3.36%
PT rev (3m)6.14%
EPS NQ rev (1m)0.29%
EPS NQ rev (3m)-54.42%
EPS NY rev (1m)-2.12%
EPS NY rev (3m)-6.19%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.88 | ||
| Fwd PE | 11.85 | ||
| P/S | 2.65 | ||
| P/FCF | 11.8 | ||
| P/OCF | 10.88 | ||
| P/B | 1.47 | ||
| P/tB | 11.2 | ||
| EV/EBITDA | 7.97 |
EPS(TTM)14.36
EY9.19%
EPS(NY)13.18
Fwd EY8.44%
FCF(TTM)13.23
FCFY8.47%
OCF(TTM)14.35
OCFY9.19%
SpS58.87
BVpS106.49
TBVpS13.95
PEG (NY)N/A
PEG (5Y)N/A
Graham Number185.49
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.34 |
F-Score5
WACC8.22%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.79%
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.98%
Revenue Next 2Y-1.74%
Revenue Next 3Y-1.31%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year4.94%
EBIT Next 3Y-0.22%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.79% in the next year.